Agents de liaison cd123 et leurs utilisations

La présente invention concerne des anticorps qui se lient de manière immunospécifique à cd123. L'invention concerne également des polynucléotides associés susceptibles de coder pour les anticorps fournis spécifiques au cd123 ou des fragments de liaison à l'antigène, des cellules exprimant les anticorps fournis ou les fragments de liaison, ainsi que des vecteurs associés et des anticorps marqués de manière détectable ou des fragments de liaison à l'antigène marqués de manière détectable. En outre, l'invent Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD 123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.